Fonkozomib 1 mg
Indonesia • Ferron Par Pharmaceuticals
Indication
Multiple Myeloma
Bortezomib for injection is indicated for the treatment of Multiple Myeloma patients who have received at least 1 prior therapy and have demonstrated disease progression on the last therapy.
Mantle Cell Lymphoma
Bortezomib for injection is indicated for the treatment of patients with Mantle Cell Lymphoma who have received at least 1 prior therapy.
Composition
Bortezomib 1 mg
Package
Dosage Forms
Powder for InjectionATC Classification
Warning
Dosage
Up to 18 Years Old
The safety and effectiveness of bortezomib in children has not been established.
18 to 65 Years Old
Dosage in relapsed multiple myeloma and mantle cell lymphoma:
The recommended dose of bortezomib is 1.3 mg/m²/dose administered as a 3 to 5 second bolus intravenous injection twice weekly for 2 weeks on days 1, 4, 8, and 11, followed by a 10-day rest period on days 12-21. This 3-week period is considered a treatment cycle. At least 72 hours should elapse between consecutive doses of bortezomib. It is recommended that patients receive 2 additional cycles of bortezomib following a confirmation of a complete response. It is also recommended that responding patients who do not achieve a complete remission receive a total of 8 cycles of bortezomib therapy.
65 Years Old and Above
No overall differences in safety of effectiveness were observed between patients ≥ 65 of age and younger patients receiving bortezomib, but greater sensitivity of some older individuals cannot be ruled out.